Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06.
Barry N, Francis RJ, Ebert MA, Koh ES, Rowshanfarzad P, Hassan GM, Kendrick J, Gan HK, Lee ST, Lau E, Moffat BA, Fitt G, Moore A, Thomas P, Pattison DA, Akhurst T, Alipour R, Thomas EL, Hsiao E, Schembri GP, Lin P, Ly T, Yap J, Kirkwood I, Vallat W, Khan S, Krishna D, Ngai S, Yu C, Beuzeville S, Yeow TC, Bailey D, Cook O, Whitehead A, Dykyj R, Rossi A, Grose A, Scott AM. Barry N, et al. Among authors: pattison da. Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):3970-3981. doi: 10.1007/s00259-023-06371-5. Epub 2023 Aug 11. Eur J Nucl Med Mol Imaging. 2023. PMID: 37563351 Free PMC article.
High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.
Kong G, Callahan J, Hofman MS, Pattison DA, Akhurst T, Michael M, Eu P, Hicks RJ. Kong G, et al. Among authors: pattison da. Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):476-489. doi: 10.1007/s00259-016-3527-x. Epub 2016 Sep 27. Eur J Nucl Med Mol Imaging. 2017. PMID: 27678267 Clinical Trial.
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.
Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang SP, Kong G, Kumar AR, Akhurst T, Pattison DA, Beaulieu A, Mooi J, Tran B, Guo C, Kalff V, Murphy DG, Jackson P, Eu P, Scalzo M, Williams S, Hicks RJ, Hofman MS. Violet J, et al. Among authors: pattison da. J Nucl Med. 2020 Jun;61(6):857-865. doi: 10.2967/jnumed.119.236414. Epub 2019 Nov 15. J Nucl Med. 2020. PMID: 31732676 Free PMC article. Clinical Trial.
68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer.
Roberts MJ, Morton A, Donato P, Kyle S, Pattison DA, Thomas P, Coughlin G, Esler R, Dunglison N, Gardiner RA, Doi SA, Emmett L, Yaxley J. Roberts MJ, et al. Among authors: pattison da. Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):477-482. doi: 10.1007/s00259-020-04944-2. Epub 2020 Jul 22. Eur J Nucl Med Mol Imaging. 2021. PMID: 32696091
Correction to: 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer.
Roberts MJ, Morton A, Donato P, Kyle S, Pattison DA, Thomas P, Coughlin G, Esler R, Dunglison N, Gardiner RA, Doi SA, Emmett L, Yaxley J. Roberts MJ, et al. Among authors: pattison da. Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):655-656. doi: 10.1007/s00259-020-04983-9. Eur J Nucl Med Mol Imaging. 2021. PMID: 32918575 No abstract available.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, McJannett MM, Stockler MR, Violet JA, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Hofman MS, et al. Among authors: pattison da. Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11. Lancet. 2021. PMID: 33581798 Clinical Trial.
66 results